Traumatic Brain Injury pipeline constitutes key companies continuously working towards developing Traumatic Brain Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
Traumatic Brain Injury Overview
According to the American Association of Neurological Surgeons, Traumatic Brain Injury (TBI) is a disruption in the normal function of the brain that can be caused by a blow, bump or jolt to the head, the head suddenly and violently hitting an object or when an object pierces the skull and enters brain tissue.
“Traumatic Brain Injury Pipeline Insight, 2022“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Traumatic Brain Injury Market.
The Traumatic Brain Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Traumatic Brain Injury Pipeline Report:
- Companies across the globe are diligently working toward developing novel Traumatic Brain Injury treatment therapies with a considerable amount of success over the years. Traumatic Brain Injury Key players such as – Hoth Therapeutics, Inc., Vasopharm GmbH, Pinteon Therapeutics, Kalytera Therapeutics Inc, KannaLife Sciences Inc, Levolta Pharmaceuticals Inc, M et P Pharma AG, Mapreg SAS, Mercaptor Discoveries Inc, MetVital Inc, NeuExcell Therapeutics Inc, NeurAegis Inc, Neuren Pharmaceuticals Ltd, NeurExo Sciences LLC, Neurodon LLC, Neuronasal LLC, NeuroNascent Inc, Neuroplast BV, NeuroTheranostics Inc, NeuroTrauma Sciences LLC, Neurotrope Bioscience Inc, New World Laboratories Inc, NoNO Inc, NuvOx Pharma LLC, Nyrada Inc, OncoSynergy Inc, Orpheris Inc, Oxeia Biopharmaceuticals Inc., and others, are developing therapies for the Traumatic Brain Injury treatment
- Traumatic Brain Injury Emerging therapies such as – VAS203 (Ronopterin), PNT001, HT-TBI, and others are expected to have a significant impact on the Traumatic Brain Injury market in the coming years.
- According to a research study by Lawrence et al., Traumatic brain injury is a major cause of mortality and morbidity
- The pioneer in targeted genetic sequencing, Tesis Biosciences, has revealed a proposed study that aims to create molecular biomarkers that can accurately distinguish mild traumatic brain injury (mTBI) from post-traumatic stress disorder (PTSD). Enabling a precise diagnosis can enhance therapies for people who are vulnerable to mTBI and PTSD, including members of the US military, athletes, and civilians of all ages
Traumatic Brain Injury Pipeline Therapeutics Assessment
- Traumatic Brain Injury Assessment by Product Type
- Traumatic Brain Injury By Stage and Product Type
- Traumatic Brain Injury Assessment by Route of Administration
- Traumatic Brain Injury By Stage and Route of Administration
- Traumatic Brain Injury Assessment by Molecule Type
- Traumatic Brain Injury by Stage and Molecule Type
DelveInsight’s Traumatic Brain Injury Report covers around products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Emerging Traumatic Brain Injury Drugs Under Different Phases of Clinical Development Include:
- VAS203 (Ronopterin): Vasopharm GmbH
- PNT001: Pinteon Therapeutics
- HT-TBI: Hoth Therapeutics, Inc.
Get a Free Sample PDF Report to know more about Traumatic Brain Injury Pipeline Assessment
Traumatic Brain Injury Pipeline Analysis:
The Traumatic Brain Injury pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the Traumatic Brain Injury treatment with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Traumatic Brain Injury Treatment.
- Traumatic Brain Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Traumatic Brain Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Traumatic Brain Injury market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Traumatic Brain Injury product details are provided in the report. Download the Traumatic Brain Injury pipeline report to learn more about the emerging Traumatic Brain Injury therapies
Traumatic Brain Injury Pipeline Market Drivers
- Rising prevalence of Traumatic Brain Injury
- Rising combinational therapy of biologics for the treatment of Traumatic Brain Injury
- Rich emerging Traumatic Brain Injury pipeline
- Acceptance of biosimilars for treatment of Traumatic Brain Injury
Traumatic Brain Injury Pipeline Market Barriers
- High cost of biologics
- Low adherence to the drugs
- Lack of daily assessment of Traumatic Brain Injury
Scope of Traumatic Brain Injury Pipeline Drug Insight
- Coverage: Global
- Key Traumatic Brain Injury Companies: Hoth Therapeutics, Inc. (NASDAQ: HOTH), Vasopharm GmbH, Pinteon Therapeutics, Kalytera Therapeutics Inc (OTCMKTS: CLAZF), KannaLife Sciences Inc, Levolta Pharmaceuticals Inc, M et P Pharma AG, Mapreg SAS, Mercaptor Discoveries Inc, MetVital Inc, NeuExcell Therapeutics Inc, NeurAegis Inc, Neuren Pharmaceuticals Ltd. (ASX: NEU), NeurExo Sciences LLC, Neurodon LLC, Neuronasal LLC, NeuroNascent Inc, Neuroplast BV, NeuroTheranostics Inc, NeuroTrauma Sciences LLC, Neurotrope Bioscience Inc, New World Laboratories Inc, NoNO Inc, NuvOx Pharma LLC, Nyrada Inc, OncoSynergy Inc, Orpheris Inc, Oxeia Biopharmaceuticals Inc (OXEA), and others
- Key Traumatic Brain Injury Therapies: VAS203 (Ronopterin), PNT001, HT-TBI, and others
- Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies
- Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers
Request for Sample PDF Report for Traumatic Brain Injury Pipeline Assessment and clinical trials
Table of Contents
| 1 | Traumatic Brain Injury Report Introduction |
| 2 | Traumatic Brain Injury Executive Summary |
| 3 | Traumatic Brain Injury Overview |
| 4 | Traumatic Brain Injury- Analytical Perspective In-depth Commercial Assessment |
| 5 | Traumatic Brain Injury Pipeline Therapeutics |
| 6 | Traumatic Brain Injury Late Stage Products (Phase II/III) |
| 7 | Traumatic Brain Injury Mid Stage Products (Phase II) |
| 8 | Traumatic Brain Injury Early Stage Products (Phase I) |
| 9 | Traumatic Brain Injury Preclinical Stage Products |
| 10 | Traumatic Brain Injury Therapeutics Assessment |
| 11 | Traumatic Brain Injury Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Traumatic Brain Injury Key Companies |
| 14 | Traumatic Brain Injury Key Products |
| 15 | Traumatic Brain Injury Unmet Needs |
| 16 | Traumatic Brain Injury Market Drivers and Barriers |
| 17 | Traumatic Brain Injury Future Perspectives and Conclusion |
| 18 | Traumatic Brain Injury Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
Download Sample PDF Report to know more about Traumatic Brain Injury drugs and therapies
Other Trending Reports
Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market
Latest Healthcare Blogs
- Genital Warts Treatment Market
- Vaccines Market Outlook
- Top Cardiac Devices For Heart Disease Prevention
- Burn Treatment Landscape
- Chlamydia Treatment
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187